Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Firebrick Pharma Limited ( (AU:FRE) ) has issued an announcement.
Firebrick Pharma Limited has announced the acceptance of its COVID-19 patent by the European Patent Office, covering the use of Nasodine Nasal Spray to reduce the viral load of SARS-CoV-2. This patent, already granted in several countries, supports the company’s strategy to expand its market presence and offers a significant tool for healthcare workers as a pre-exposure prophylaxis against COVID-19.
More about Firebrick Pharma Limited
Firebrick Pharma is a pharmaceutical innovator focusing on developing and commercializing novel formulations and uses of povidone-iodine (PVP-I). The company has developed Nasodine Nasal Spray, which is already available in the United States, Singapore, and Fiji & South Pacific, with plans to launch in the Philippines in 2026.
Average Trading Volume: 80,245
Technical Sentiment Signal: Buy
See more insights into FRE stock on TipRanks’ Stock Analysis page.